25 results on '"Ribaudo, Heather J"'
Search Results
2. Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study
3. HIV-1 Drug Resistance in Subjects with Advanced HIV-1 Infection in Whom Antiretroviral Combination Therapy Is Failing: A Substudy of AIDS Clinical Trials Group Protocol 388
4. A Multilevel Analysis of Longitudinal Ordinal Data: Evaluation of the Level of Physical Performance of Women Receiving Adjuvant Therapy for Breast Cancer
5. Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s
6. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s
7. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir
8. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s
9. Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257
10. Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230
11. Editorial Commentary: Cost-Effectiveness Evaluation to Inform Clinical Trial Design
12. Racial Differences in Response to Antiretroviral Therapy for HIV Infection: An AIDS Clinical Trials Group (ACTG) Study Analysis
13. Clinical and Genetic Determinants of Plasma Nevirapine Exposure Following an Intrapartum Dose to Prevent Mother-to-Child HIV Transmission
14. Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure
15. Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-Boosted Atazanavir in AIDS Clinical Trials Group Study A5202
16. Highly Active Antiretroviral Therapy and Adverse Birth Outcomes Among HIV-infected Women in Botswana
17. No Risk of Myocardial Infarction Associated With Initial Antiretroviral Treatment Containing Abacavir: Short and Long-Term Results from ACTG A5001/ALLRT
18. Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
19. Instantaneous Inhibitory Potential Is Similar to Inhibitory Quotient at Predicting HIV-1 Response to Antiretroviral Therapy
20. Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure
21. Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095
22. Efavirenz-Based Regimens in Treatment-Naive Patients with a Range of Pretreatment HIV-1 RNA Levels and CD4 Cell Counts
23. Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1-Infected Subjects
24. Plasma HIV-1 RNA Dynamics in Antiretroviral-Naive Subjects Receiving Either Triple-Nucleoside or Efavirenz-Containing Regimens: ACTG A5166s
25. A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens versus a 3-Drug Regimen, in Advanced Human Immunodeficiency Virus Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.